• Publications
  • Influence
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer.
The discovery of a targeted therapeutic compound along with its companion predictive biomarker is a major goal of clinical development for a personalized anticancer therapy to date. Here we presentExpand
  • 101
  • 6
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
Objective To assess a new adenovirus-based immunotherapy as a novel treatment approach to chronic hepatitis B (CHB). Methods TG1050 is a non-replicative adenovirus serotype 5 encoding a unique largeExpand
  • 64
  • 1
Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Development of active targeted immunotherapeutics is a rapid developing field in the arena of chronic infectious diseases. The question of repeated, closely spaced administration ofExpand
  • 4
O031 : TG1050, a novel immunotherapeutic to treat chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models
Methods: We infected mice with a hepatotropic virus and challenged these mice by injecting TNF. Using knockout mice, as well as biochemical and multiparametric histological methods we analyzed theExpand
  • 2
TG1050, a novel immunotherapeutic for the treatment of chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models
s / Journal of Clinical Virology 69 (2015) 223–246 227 evaluated with serial dilutions (106–100 IU/mL; Roche). The quantitative correlation and lower limit of detection were evaluated by use ofExpand
449 TOWARDS THE DEVELOPMENT OF A THERAPEUTIC VACCINE TO TREAT CHRONIC HBV INFECTION: AD5-BASED VACCINES ENCODING MULTIPLE HBV ANTIGENS INDUCE STRONG T-CELL RESPONSES IN PRE-CLINICAL MODELS
P =0.0049; A vs C P < 0.0001; B vs C P =0.0001). Forty seven percent of patients in group A and B were HLA-A2 positive. Tim-3/PD-1 HBV-specific CD8 T cells were 61.95% (median, range 18.7%-95.5%),Expand
Glycolipid Antigen Expression in Human Lung Cancer 1
Several mouse monoclonal antibodies which recognize carbohydrate sequences distinguish between different types of human lung cancer immunohistologically. These antibodies bind to glycolipid antigensExpand